HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Spero Therapeutics, maintaining a price target of $7.
October 03, 2024 | 11:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Spero Therapeutics, maintaining a price target of $7, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $7 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Spero Therapeutics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100